Pancreatic adenocarcinoma pathway (WP4263)
Homo sapiens
Infiltrating ductal adenocarcinoma is the most common malignancy of the pancreas. When most investigators use the term 'pancreatic cancer' they are referring to pancreatic ductal adenocarcinoma (PDA). Normal duct epithelium progresses to infiltrating cancer through a series of histologically defined precursors, Pancreatic Intraepithelial Neoplasia (PanINs: https://pathology.jhu.edu/pancreas/professionals/DuctLesions.php). The overexpression of HER-2/neu (ERBB2) and activating point mutations in the K-ras gene occur early, inactivation of the p16 gene (CDKN2A) at an intermediate stage, and the inactivation of p53, SMAD4, and BRCA2 occur relatively late. Activated K-ras engages multiple effector pathways. Although EGF receptors are conventionally regarded as upstream activators of RAS proteins, they can also act as RAS signal transducers via RAS-induced autocrine activation of the EGFR family ligands. Moreover, PDA shows extensive genomic instability and aneuploidy. Telomere attrition and mutations in p53 and BRCA2 are likely to contribute to these phenotypes. Inactivation of the SMAD4 tumor suppressor gene leads to loss of the inhibitory influence of the transforming growth factor-beta signaling pathway. The progression of disease and associated mutations is defined based on the arrow at the top, from left to right. Phosphorylation sites were added based on information from PhosphoSitePlus (R), www.phosphosite.org.
Authors
Kristina Hanspers , Egon Willighagen , and Eric WeitzActivity
Discuss this pathway
Check for ongoing discussions or start your own.
Cited In
- Shared mechanisms and crosstalk of COVID-19 and osteoporosis via vitamin D (2022).
- A Practical Strategy for Exploring the Pharmacological Mechanism of Luteolin Against COVID-19/Asthma Comorbidity: Findings of System Pharmacology and Bioinformatics Analysis (2024).
Are you planning to include this pathway in your next publication? See How to Cite and add a link here to your paper once it's online.
Organisms
Homo sapiensCommunities
CPTAC Diseases PancCanNetAnnotations
Pathway Ontology
disease pathway cancer pathway Jak-Stat signaling pathway phosphatidylinositol 3-kinase-Akt signaling pathwayDisease Ontology
pancreatic adenocarcinomaCell Type Ontology
pancreatic ductal cellReferences
- Potential tumor suppressive pathway involving DUSP6/MKP-3 in pancreatic cancer. Furukawa T, Sunamura M, Motoi F, Matsuno S, Horii A. Am J Pathol. 2003 Jun;162(6):1807–15. PubMed Europe PMC Scholia
- PhosphoSitePlus, 2014: mutations, PTMs and recalibrations. Hornbeck PV, Zhang B, Murray B, Kornhauser JM, Latham V, Skrzypek E. Nucleic Acids Res. 2015 Jan;43(Database issue):D512-20. PubMed Europe PMC Scholia
- RIPK4/PEBP1 axis promotes pancreatic cancer cell migration and invasion by activating RAF1/MEK/ERK signaling. Qi ZH, Xu HX, Zhang SR, Xu JZ, Li S, Gao HL, et al. Int J Oncol. 2018 Apr;52(4):1105–16. PubMed Europe PMC Scholia